

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED

北京同仁堂國藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3613)

CHANGE OF CHIEF EXECUTIVE OFFICER

The board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) herby announces that with effect from 18 April 2019, Ms. Ding Yong Ling (“**Ms. Ding**”) has resigned as the chief executive officer of the Company as she wishes to focus on her role as chairman of the Board of the Company to lead the Board to determine the strategic direction of the Group and is responsible for the high-level oversight of the management whilst continuing with her present role as an executive director, chairman of the Board, member of the Nomination Committee and member of the Remuneration Committee of the Company.

Ms. Ding has confirmed that she has no disagreement with the Board and there are no other matters that need to be brought to the attention of the shareholders of the Company in relation to her resignation as the chief executive officer of the Company.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Board further announces that Mr. Zhang Huan Ping (“**Mr. Zhang**”), currently an executive director and deputy general manager of the Company, has been appointed as the chief executive officer of the Company with effect from 18 April 2019.

The biographical details of Mr. Zhang are set out as follows:

Zhang Huan Ping, aged 58, is an executive Director and a deputy general manager of the Company and is mainly responsible for production. Mr. Zhang joined the Company as a deputy general manager in May 2008 and was appointed as a Director on 1 February 2011. Mr. Zhang joined Beijing Tong Ren Tang Group in May 1979 and formerly served as the deputy manager of Tong Zhou Medicine Factory and Medicine Wine Factory of Tong Ren Tang Ltd., and an executive director of Tong Ren Tang Technologies Co. Ltd., a joint stock limited company established in the PRC on 22 March 2000, the H shares of which have been listed on GEM since 2000 and have been transferred to the Main Board since July 2010, and is the immediate holding company of the Company. Mr. Zhang graduated in major of economic management from the Correspondence Institute of Party School of the Central

Committee of the Communist Party of China in December 2000. He is a pharmacist-in-charge conferred by Beijing Intermediate Professional Technical Titles Evaluation Committee in November 2002.

A service agreement (the “**Agreement**”) was entered into between the Company and Mr. Zhang since 15 April 2019 for a period of three years. Pursuant to the Agreement, Mr. Zhang will not receive any director’s fee as an executive director of the Company. For the year ended 31 December 2018, Mr. Zhang was entitled to a total emolument of HK\$1,725,000 comprising salaries and other benefits and retirement benefit scheme contributions, as determined by the Board. The emolument of Mr. Zhang as the chief executive officer of the Company shall be determined by the Board with reference to his duties and responsibilities with the Company and the Company’s remuneration policy.

As at the date of this announcement, Mr. Zhang does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

As at the date of this announcement, Mr. Zhang has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Mr. Zhang does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company nor does she hold any other position with the Company or any of its subsidiaries.

Save as the above disclosed, Mr. Zhang has confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the shareholders of the Company in connection with the aforesaid appointment.

By order of the Board
Beijing Tong Ren Tang
Chinese Medicine Company Limited
Ding Yong Ling
Chairman

Hong Kong, 18 April 2019

As at the date of this announcement, the Board comprises the executive directors, namely Ms. Ding Yong Ling (Chairman), Mr. Zhang Huan Ping and Ms. Lin Man; and the independent non-executive directors, namely Mr. Tsang Yok Sing, Jasper, Mr. Zhao Zhong Zhen and Mr. Chan Ngai Chi.